Literature DB >> 23023405

Atypical continuous keratitis in a case of rheumatoid arthritis accompanying severe scleritis.

Masayuki Hata1, Takahiro Nakamura, Chie Sotozono, Kyoko Kumagai, Shigeru Kinoshita, Yasuo Kurimoto.   

Abstract

PURPOSE: Rheumatoid arthritis (RA) often presents with ocular complications: typically dry eye, peripheral corneal ulcer, and scleritis. We report for the first time a case of severe scleritis with RA, accompanying atypical continuous keratitis, which apparently differs from typical peripheral ulcerative keratitis (PUK).
METHODS: Observational case report.
RESULTS: A 68-year-old woman with RA presented at our hospital complaining of worsening arthritis accompanying ocular injection and discharge. On examination, nodular scleritis and peripheral corneal infiltration were noted. In addition to administering topical steroid and antibiotics, cyclosporine and an oral steroid were added because of the patient's worsening scleritis. Despite gradual improvement of the scleritis, the efficacy of the additional treatments was limited. Four months after initial treatment, the patient presented with uveitis, thought to be caused by a herpetic virus. Antivirus treatment was effective for the uveitis, but atypical continuous keratitis suddenly appeared. The keratitis was located from 4-o'clock to 10-o'clock positions continuously in the midperipheral cornea and apparently differed from herpetic keratitis or PUK as typically seen in RA cases. Immune reaction was suspected, and the keratitis improved within 2 weeks. After that, the introduction of an anti-tumor necrosis factor α drug (infliximab) completely resolved the severe scleritis and there was no recurrence of ocular inflammation.
CONCLUSION: As is shown in this case, RA can present with atypical continuous keratitis, thought to be a manifestation of an immunologic reaction other than PUK. In addition, although immunosuppressants are often used for the treatment of RA with scleritis, the efficacy is limited. Infliximab may be a useful treatment for treatment-resistant scleritis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23023405     DOI: 10.1097/ICO.0b013e31826218c7

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  8 in total

Review 1.  Peripheral Ulcerative Keratitis: A Review.

Authors:  Kiana Hassanpour; Reem H ElSheikh; Amir Arabi; Charles R Frank; Abdelrahman M Elhusseiny; Taher K Eleiwa; Shiva Arami; Ali R Djalilian; Ahmad Kheirkhah
Journal:  J Ophthalmic Vis Res       Date:  2022-04-29

Review 2.  The eye: a window of opportunity in rheumatoid arthritis?

Authors:  Louis Tong; Julian Thumboo; York Kiat Tan; Tien-Yin Wong; Salvatore Albani
Journal:  Nat Rev Rheumatol       Date:  2014-06-10       Impact factor: 20.543

Review 3.  Infliximab for peripheral ulcerative keratitis treatment.

Authors:  Valentín Huerva; Francisco J Ascaso; Andrzej Grzybowski
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

Review 4.  Peripheral Ulcerative Keratitis Associated with Autoimmune Disease: Pathogenesis and Treatment.

Authors:  Yan Cao; Wensong Zhang; Jie Wu; Hong Zhang; Hongyan Zhou
Journal:  J Ophthalmol       Date:  2017-07-13       Impact factor: 1.909

5.  Two cases of perforated corneal ulcers complicating rheumatoid arthritis treated successfully by biological therapy.

Authors:  Sara Benchérifa; Bouchra Amine; Imane El Binoune; Samira Rostom; Rachid Bahiri
Journal:  BMC Rheumatol       Date:  2020-02-07

6.  Recurrent and refractory corneal perforation secondary to rheumatoid arthritis treated with infliximab.

Authors:  Ahmed Al Saleh; Abdullah S Al Saleh; Abdulmalik Al Qahtani
Journal:  Saudi J Ophthalmol       Date:  2021-02-27

7.  Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis.

Authors:  Philip B Meadow; Jacqueline Nguyen; Keerthana Kesavarapu
Journal:  Case Rep Rheumatol       Date:  2014-06-17

Review 8.  Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review.

Authors:  Jurgen Sota; Matteo-Maria Girolamo; Bruno Frediani; Gian Marco Tosi; Luca Cantarini; Claudia Fabiani
Journal:  Ophthalmol Ther       Date:  2021-09-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.